MedPath

Based on the theory of 'liver and kidney homology' to explore the clinical application of TCM prevention and treatment in PATIENTS with HR-positive breast cancer

Not Applicable
Recruiting
Conditions
Breast Cancer
Registration Number
ITMCTR2200005735
Lead Sponsor
onghua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
Female
Target Recruitment
Not specified
Inclusion Criteria

1. Aged between 18 and 65;
2. Patients diagnosed as breast cancer by pathology and HR positive by immunohistochemistry;
3. Completed surgery, chemotherapy, radiotherapy, and/or targeted therapy;
4. Have received AIs (anastrozole, Letrozole, exemestane) for at least 2 months;
5. TCM syndrome differentiation belongs to liver and kidney deficiency (symptoms include tenderness of waist and knee, stiffness of joints, dizziness, etc.);
6.KPS score =60;
7. The expected survival is more than 6 months;
8. Signed the informed consent and voluntarily accepted the treatment plan of the study.

Exclusion Criteria

1. Bone mineral diseases: such as hypoparathyroidism or hyperthyroidism, malformed osteitis, osteogenesis imperfection, osteomalacia, etc.;
2. Diseases that affect bone metabolism, such as Cushing's syndrome, hyperthyroidism, rheumatism or rheumatoid arthritis;
3. Steroid hormones or anticonvulsants were used for more than 6 months before the study;
4. Used hormone replacement therapy within 6 months, such as glucocorticoid, parathyroid hormone, estrogen, etc.;
5. Had surgery related to extremities within 6 months;
6. Complicated with serious primary diseases of cardiovascular, liver, kidney and hematopoietic systems;
7. Patients with obvious disease progression and distant metastasis during the study;
8. Psychopaths with cognitive impairment or mental abnormalities.

Study & Design

Study Type
Interventional study
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
WOMAC;
Secondary Outcome Measures
NameTimeMethod
Bone density test;TCM symptom and sign scoring;Growth hormone(GH);Bone metabolism indicators (25-Hydroxy-vitamin-D, ß-CTX, osteocalcin);
© Copyright 2025. All Rights Reserved by MedPath